Explore all the latest information in myelodysplastic syndromes, arranged by key congresses and meetings. Listed below are recently updated congresses and meetings.
How can immunotherapy be used in MDS?
During the European School of Haematology (ESH) 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to...
What are the new approaches for anemia treatment in MDS?
During the European School of Haematology (ESH) 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis -...
Maintenance therapy after allo-HSCT in patients with MDS
Allogeneic hematopoietic stem cell transplant (allo-HSCT) remains the only curative treatment for patients with myelodysplastic syndromes...
Residual circulating tumor DNA as a prognostic biomarker in patients with AML/MDS
In the retrospective setting, residual circulating tumor DNA (ctDNA) can be useful as a prognostic biomarker to...
Initiation of the first-in-human trial of allogeneic NKG2D-directed CAR NK-cell therapy to treat R/R AML or high-risk R/R MDS
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are...
How can we tailor treatment to improve outcome in MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Rena Buckstein, Sunnybrook Health...
What are the challenges in diagnosing MDS?
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub spoke to Aziz Nazha, Cleveland Clinic, Cleveland, US. We asked:...
Targeted therapeutics in MDS – what’s the current state of play?
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub podcast channel spoke to Dr David Sallman,...
Society of Hematologic Oncology
American Society of Clinical Oncology
American Society of Hematology
European Hematology Association
European School of Haematology
ESH ERYTHRO 2021
European Society for Blood and Marrow Transplantation